Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

compared to 38 days at both September 30, 2012 and December 31, 2011.

The Company's investor conference call will be webcast on January 25 at 9:00 am ET.  Management's commentary and presentation slides will be available through www.covance.com

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues of approximately $2.2 billion, global operations in more than 30 countries, and more than 11,750 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage develo
'/>"/>

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ( ... "Inhaled Drug Delivery (London, UK - November 19-20, 2015)" ... Drug Delivery meeting will cover industry case studies, regulatory ... The Co-Chairmen are Dr Steven Nichols , OINP ... Mylan. Companies participating include: ...
(Date:9/2/2015)... 2015   Gulf Coast Tattoo Removal is the first ... Astanza Duality laser in Southern Mississippi . Gulf ... regret and take back control of their skin. The clinic is ... services to Biloxi , Gulfport ... regret being as prevalent as it is, I was surprised by ...
(Date:9/2/2015)... , Sept. 2, 2015 Research ... addition of the "Medical Device Studies: Clinical ... conference to their offering. This ... are involved in gathering clinical evidence required for ... is required for all medical devices and the ...
Breaking Medicine Technology:Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... 9 DOR BioPharma, Inc. (DOR or the Company) ... today that it has received Protocol Assistance feedback from ... its confirmatory, pivotal, Phase 3 clinical trial evaluating its ... Graft-versus-Host Disease (GI GVHD). , , The ...
... Potential Benefits of Exenatide to be Prospectively Assessed in Large ... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli ... results from a meta-analysis of cardiovascular (CV) events that showed ... injection use compared to a pooled comparator group treated with ...
Cached Medicine Technology:DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 2DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 3DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 4DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 5DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 6DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD 7Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 2Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 3Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 4Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 5Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009 6
(Date:9/2/2015)... , ... September 03, 2015 , ... ... and frequently listed among the most influential leaders in healthcare, will offer the ... Coalition, to take place October 15-16, 2015, in Palm Harbor, Florida, at the ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
(Date:9/2/2015)... ... ... Sara Bleich, Ph.D., associate professor of health and policy ... recognized scholar on obesity prevention and control, has been selected for the prestigious ... graduate of Garrison Forest School, an all-girls’ independent school in Owings Mills, Md., ...
(Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system ... complex of the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or ... of any given guide RNA (sgRNA or crRNA) to create a break in the ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4
... , , , ANNAPOLIS, ... PIP ), a biodefense company developing medical countermeasures against biological ... agreements for the issuance of 2-year, 10% unsecured senior convertible ... private placement of approximately $19.3 million. , , ...
... July 27 Health Robotics today announced,that it has ... to market,implement, and support its I.V. Workflow Engine and ... North America. One of,its software modules (OncoCube) has already ... University of Colorado Hospital [Denver], in,addition to all-digital ...
... , , , ... reveals that adults living in the country,s fifth largest city are ... and complex conditions. Many commonly used therapy classes including drugs to ... have experienced increases in adults 20 and older. , ...
... , Trinitas Comprehensive Cancer Center in Elizabeth, ... chemotherapy program in place , , LOS ... a variety of cancers--along with projections from the National Comprehensive Cancer Network ... by 2013--raise questions for both clinicians and patients with regard to the ...
... COLD SPRING HARBOR, N.Y., July 27 AccuVein LLC, ... illumination device, today announced that its quality system has received ... to customers around the globe AccuVein,s commitment to the quality ... and delivery procedures. , , ...
... , FRANKLIN, Mass., July 27 PLC ... innovative cardiac and vascular medical device-based technologies, today announced it ... capabilities provided by RenalGuard(R) from the Canadian Intellectual Property Office ... patent for RenalGuard in Canada. , , ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 2Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 2Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 4Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 2Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 3Health News:AccuVein Achieves Quality System Milestone 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2
RCB™ Rotator Cuff Buttress is a completely resorbable plate that will alleviate suture migration in open or mini-Open rotator cuff repairs....
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... an absorbable co-polymer synthesized from all-natural ... glycolic acid. Unlike the homopolymers in ... acid (PLLA) or 100% poly-glycolic acid ... (without crystallinity), meaning that its degradation ...
... Medicine™ AnchorSew™ 3 mm is a resorbable repair ... Medicine ArthroSew suturing device to attach soft tissue ... implanted into a prepared hole in the bone, ... soft tissue anchors are made of a resorbable ...
Medicine Products: